Treatment of patients with high risk DLBCL

被引：0
|
作者：
Keller, U. [1 ]
机构：
[1] Tech Univ Munich, Innere Med 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V105
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [41] Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT
    Cabero Martinez, Almudena
    Diaz Gonzalez, Luis Gonzaga
    Montes, Carlos
    Cortes-Rodriguez, Maria
    Gutierrez, Norma C.
    Baile Gonzalez, Monica
    Bacelar, Ana Garcia
    Lopez Parra, Miriam
    Cristobal Canadas, Jose
    Gabriel Villanueva, Juan
    Diaz Galvez, Francisco Javier
    Penarrubia-Ponce, Maria
    Fernandez Ferrero, Silvia Maria
    Queizan Hernandez, Jose Antonio
    Cabezudo, Miguel
    De Cabo Lopez, Erik
    Villaescusa, Teresa
    Tamayo, Pilar
    Garcia-Sanz, Ramon
    Garcia-Sancho, Alejandro Martin
    BLOOD, 2023, 142
  • [42] Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients
    Pfreundschuh, Michael
    Murawski, Niels
    Zeynalova, Samira
    Ziepert, Marita
    Loeffler, M.
    Haenel, Matthias
    Dierlamm, Judith
    Keller, Ulrich
    Dreyling, Martin
    Truemper, Lorenz
    Frickhofen, Norbert
    Huenerlituerkoglu, Ali-Nuri
    Schmitz, Norbert
    Poeschel, Viola
    Rixecker, Tanja
    Berdel, Christian
    Ruebe, Christian
    Held, Gerhard
    Zwick, Carsten
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (03) : 410 - 420
  • [43] Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL
    Leslie, Lori A.
    Kothadia, Sejal
    Protomastro, Ewelina
    Greenberg, Patricia J.
    Andrews, Tracy
    McNeill, Ann
    Iida, Hoshiyuki
    Skarbnik, Alan P.
    Yang, Xiao
    Bhattacharyya, Pritish K.
    Chow, Kar Fai
    Goldberg, Stuart L.
    Pecora, Andrew L.
    Feldman, Tatyana A.
    Goy, Andre
    BLOOD, 2017, 130
  • [44] Interim PET and DLBCL Treatment
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (03) : 25N - 25N
  • [45] Refractory DLBCL: Challenges and Treatment
    Goldfinger, Mendel
    Cooper, Dennis L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : 140 - 148
  • [46] Risk Stratification of DLBCL Patients According to NCCN-IPI in Our Hospital
    Kazuma, Yasuhiro
    Aoki, Kazunari
    Ochi, Yotaro
    Koba, Yusuke
    Shimomura, Yoshimitsu
    Nagahata, Yosuke
    Yamauchi, Nobuhiko
    Ono, Yuichiro
    Hiramoto, Nobuhiro
    Tabata, Sumie
    Yonetani, Noboru
    Matsushita, Akiko
    Hashimoto, Hisako
    Ishikawa, Takayuki
    BLOOD, 2014, 124 (21)
  • [47] Radiation And Stroke Death Risk In DLBCL Patients, A Population-Based Study
    Szeja, S.
    Dandapani, S. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E755 - E755
  • [48] Primary high dose therapy in high risk DLBCL - Is biology more important than dose intensity?
    Baumgarten, A.
    Veelken, H.
    Engelhardt, M.
    Finke, J.
    Marks, R.
    ONKOLOGIE, 2012, 35 : 40 - 40
  • [49] Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse
    Masahiro Akimoto
    Takuya Miyazaki
    Hiroyuki Takahashi
    Yusuke Saigusa
    Takaaki Takeda
    Yuto Hibino
    Mayumi Tokunaga
    Takuma Ohashi
    Ayako Matsumura
    Haruka Teshigawara
    Taisei Suzuki
    Hiroshi Teranaka
    Yuki Nakajima
    Kenji Matsumoto
    Chizuko Hashimoto
    Katsumichi Fujimaki
    Hiroyuki Fujita
    Rika Sakai
    Shin Fujisawa
    Hideaki Nakajima
    International Journal of Hematology, 2024, 119 (2) : 164 - 172
  • [50] Predictive medicine: Individualized pretherapeutic identification of high-risk diffuse large-B-cell lymphoma (DLBCL) patients
    Valet, GK
    Hoeffkes, HG
    CYTOMETRY PART A, 2004, 59A (01) : 38 - 38
12345